2 results
Approved WMOCompleted
Primary:To evaluate if progression-free survival from randomization to progression or death during second-line therapy (total PFS) of sorafenib followed by pazopanib is non-inferior compared to pazopanib followed by sorafenib.Secondary:1. Time from…
Approved WMORecruiting
Using state of the art CMR imaging techniques, we will characterize ablation lesions in the early phase after pulmonary vein isolation, and relate findings to (1) the ablation scar at 3 months follow up and (2) atrial fibrillation-free survival at 1…